In this recorded presentation from the Advancing Precision Medicine conference (November 1, 2024), Dr. Mark Roschewski, Clinical Director of the Lymphoid Malignancies Branch at the NCI's Center for Cancer Research, discusses the promising applications of ultra-sensitive ctDNA-MRD detection to drive more personalized treatment paradigms in lymphoma.

At the time of this presentation Foresight CLARITY is a lab-developed test for the detection of minimal residual disease (MRD) in B-cell lymphoma. This test is for research use only and is not intended for use in diagnostic procedures.

свернуть